Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. (2020)
Attributed to:
High Throughput Science - Genomic and metabolmic analysis of haemorrhagic in the China Kadoorie Biobank
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1126/scitranslmed.aay6570
PubMed Identifier: 32581134
Publication URI: http://europepmc.org/abstract/MED/32581134
Type: Journal Article/Review
Volume: 12
Parent Publication: Science translational medicine
Issue: 549
ISSN: 1946-6234